Systemic Therapy Combined with Locoregional Therapy Improved Survival in Oligometastatic Breast Cancer: A Single-Center Retrospective Cohort Study
Table 4
Univariate analysis and multivariate analysis of progression-free survival.
Variable
Univariate analysis
Multivariate analysis
Hazard ratio
95% CI
value
Hazard ratio
95% CI
value
Hormone receptor status
HR+
1
1
HR-
1.719
1.264-2.338
0.001
1.636
1.190-2.249
0.002
HER2 status
HER2+
1
HER2-
1.122
0.824-1.528
0.464
No. of metastatic lesions
1
1
1
2-3
1.457
0.936-2.268
0.095
1.192
0.737-1.929
0.474
4-5
1.656
1.116-2.456
0.012
1.140
0.697-1.864
0.602
Chest or skin metastasis
No
1
1
Yes
0.780
0.537-1.131
0.190
0.909
0.613-1.348
0.635
Lymph node metastasis
No
1
Yes
0.857
0.629-1.168
0.329
Lung metastasis
No
1
Yes
1.212
0.865-1.697
0.263
Liver metastasis
No
1
1
Yes
1.294
0.904-1.853
0.159
1.035
0.712-1.506
0.856
Bone metastasis
No
1
Yes
1.068
0.775-1.472
0.686
DFI (months)
<12
1
1
12-24
0.841
0.540-1.307
0.441
0.785
0.498-1.237
0.296
≥24
0.695
0.483-1.002
0.051
0.626
0.427-0.918
0.017
Treatment approach
ST alone
1
1
ST to LRT
0.527
0.341-0.814
0.004
0.518
0.319-0.840
0.008
LRT to ST
0.484
0.328-0.715
<0.001
0.491
0.310-0.778
0.002
Abbreviations: CI: confidence interval; HR: hormone receptor; HER2: human epidermal growth factor receptor 2; DFI: disease-free interval; ST to LRT: systemic therapy followed by locoregional therapy; LRT to ST: locoregional therapy followed by systemic therapy; ST: systemic therapy.
